25 March 2020
Botanix announces top line BTX 1204 atopic dermatitis data
• BTX 1204 did not achieve statistical significance in the primary and secondary endpoints in its
Phase 2 atopic dermatitis study
• Botanix will be finalising a comprehensive review of the study data and will provide an update
on the BTX 1204 program and its broader dermatology platform
Philadelphia PA and Sydney Australia, 25 March 2020: Clinical stage synthetic cannabinoid company
Botanix Pharmaceuticals Limited (ASX:BOT, “Botanix” or “the Company”) today announced that BTX
1204 did not meet the primary endpoint in its Phase 2 study evaluating the safety and efficacy in
patients with moderate atopic dermatitis (“1204 Study”).
Sad
- Forums
- ASX - By Stock
- Ann: Antimicrobial Platform Update and Launch of BTX 1801 Study
25 March 2020Botanix announces top line BTX 1204 atopic...
Featured News
Add BOT (ASX) to my watchlist
(20min delay)
|
|||||
Last
27.5¢ |
Change
-0.015(5.17%) |
Mkt cap ! $433.1M |
Open | High | Low | Value | Volume |
28.5¢ | 29.0¢ | 27.5¢ | $1.164M | 4.100M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 534239 | 27.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
28.0¢ | 77302 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 534239 | 0.275 |
28 | 1101521 | 0.270 |
7 | 245317 | 0.265 |
15 | 539228 | 0.260 |
6 | 281008 | 0.255 |
Price($) | Vol. | No. |
---|---|---|
0.280 | 77302 | 2 |
0.285 | 206615 | 3 |
0.290 | 236155 | 4 |
0.295 | 251724 | 4 |
0.300 | 400955 | 9 |
Last trade - 16.10pm 28/05/2024 (20 minute delay) ? |
|
|||||
Last
28.0¢ |
  |
Change
-0.015 ( 2.61 %) |
|||
Open | High | Low | Volume | ||
28.5¢ | 29.0¢ | 27.5¢ | 2348390 | ||
Last updated 15.59pm 28/05/2024 ? |
Featured News
BOT (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online